Åke Berglund

Uppsala University — Sweden

Medicine · Health Sciences

28h-index5.2kcitations68works8.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(35), Cancer Treatment and Pharmacology(17), Gastric Cancer Management and Outcomes(14), Colorectal Cancer Surgical Treatments(13), Colorectal and Anal Carcinomas(12)

Publications67 total

Freezing lizards, loving creatures, and flying pigs: tracing students’ meaning making about evolution through student-generated comics
International Journal of Science Education·2025Open Access
Total neoadjuvant treatment using short-course radiotherapy and four CAPOX cycles in locally advanced rectal cancer with high-risk criteria for recurrence: a Swedish nationwide cohort study (LARCT-US)
EClinicalMedicine·2024· 16 citedOpen Access
The effect of BRAFV600E mutation on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer – A post-hoc exploratory analysis of the randomized NORDIC9-study
Journal of Geriatric Oncology·2023Open Access
Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery
Annals of Surgery·2023· 312 citedOpen Access
Prognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy – The randomized NORDIC9-study
Journal of Geriatric Oncology·2022· 10 citedOpen Access
The Prognostic Value of Pre-Treatment Circulating Biomarkers of Systemic Inflammation (CRP, dNLR, YKL-40, and IL-6) in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy—The Randomized NORDIC9-Study
Journal of Clinical Medicine·2022· 13 citedOpen Access
Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer
Cancer Treatment and Research Communications·2022· 5 citedOpen Access
Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy—The Randomized NORDIC9-Study
Cancers·2021· 20 citedOpen Access
Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer: Nordic 8 results
Annals of Oncology·2019Open Access
Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial
˜The œLancet. Gastroenterology & hepatology·2019· 67 cited
NORDIC9: A randomized phase II trial comparing first-line palliative full-dose monotherapy (S-1) with reduced dose-combination therapy (SOx) in older and frail patients with metastatic colorectal cancer (mCRC)
Annals of Oncology·2018· 2 citedOpen Access
Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9
BMC Cancer·2017· 15 citedOpen Access
Pre-planned safety analysis of NORDIC 9: A randomized trial comparing full dose monotherapy (S-1) with reduced dose combination therapy (S-1/oxaliplatin) in older chemo-naive patients with metastatic colorectal cancer (mCRC).
Journal of Clinical Oncology·2017· 1 cited
Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial
The Lancet Oncology·2017· 611 cited
NORDIC9: A randomized phase II trial exploring treatment of older patients with metastatic colorectal cancer (mCRC) by comparing full dose monotherapy (S-1 followed by irinotecan) with reduced combination regimen (S-1/oxaliplatin followed by S-1/irinotecan)
Annals of Oncology·2016Open Access
First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies
Investigational New Drugs·2015· 30 cited
A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial
Annals of Oncology·2015· 56 citedOpen Access
The response to vaccination against influenza A(H1N1) 2009, seasonal influenza and<i>Streptococcus pneumoniae</i>in adult outpatients with ongoing treatment for cancer with and without rituximab
Acta Oncologica·2014· 57 citedOpen Access
A randomized pilot study with daily walking during adjuvant chemotherapy for patients with breast and colorectal cancer
Acta Oncologica·2014· 84 citedOpen Access
A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial
Annals of Oncology·2013· 74 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Bengt Glimelius(36), Per Byström(14), Halfdan Sørbye(11), Per Pfeiffer(10), Jan‐Erik Frödin(9), Peter Nygren(8), Camilla Qvortrup(8), Pia Österlund(6), Hans Hagberg(5), Anders Jakobsen(5), Stine Brændegaard Winther(5), Eva Hofsli(5), Morten Brændengen(4), Birgitta Johansson(4), Gábor Liposits(4), Halla Skúladóttir(4), Laurids Østergaard Poulsen(4), Jesper Ryg(4), Kjell M. Tveit(3), Lars Påhlman(3)